Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2026)

Xeris Biopharma Holdings has reported Research & Development for 7 years, with the latest figure at $8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 13.29% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $32.2 million (up 26.29% YoY), and the FY2025 full-year result was $31.2 million, up 21.93% from the prior year.
• Research & Development for Q1 2026 stood at $8.8 million, up from $7.9 million in the prior quarter.
• The five-year high for Research & Development was $8.8 million in Q1 2026, with the low at $3.7 million in Q2 2022.
• Historically, Research & Development has averaged $6.4 million across 5 years, with a median of $6.1 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development tumbled 50.85% — and 2023, when it soared 63.72%.
• Xeris Biopharma Holdings' Research & Development stood at $5.0 million in 2022, then climbed by 28.8% to $6.4 million in 2023, then dropped by 4.54% to $6.1 million in 2024, then advanced by 29.25% to $7.9 million in 2025, then climbed by 11.54% to $8.8 million in 2026.
• The last three Research & Development figures came in at $8.8 million (Q1 2026), $7.9 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.